Respiratory disorders
Conditions
Interventions
Group 1:Remazolam + Remifentanil
Group 2:Propofol + Remifentanil
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients who are going to undergo fiberoptic bronchoscopy; 2. Aged 18-65 years, gender is not limited; 3. Body mass index (BMI) 18.5-30 kg/m^2; 4. ASA I-III level; 5. Voluntarily participated and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients undergoing emergency bronchoscopy diagnosis and treatment; 2. Patients with contraindications to sedation/anaesthesia or a history of abnormal recovery from sedation/anaesthesia; 3. Known allergic to local anesthetics, propofol, benzodiazepines, opioids and their rescue drugs; 4. Those with a history of severe heart, brain, liver, kidney and metabolic diseases; 5. Patients who are deemed unsuitable by the investigator to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of blood pressure drop; | — |
Secondary
| Measure | Time frame |
|---|---|
| Doctor's /Patient's satisfaction ;Wake up time;MOAA/S sedation depth score; | — |
Countries
China
Contacts
Public ContactLyu Yunqi
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed